NCT03905538: Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors

NCT03905538
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Ph+ase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 13 Years to 25 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03905538

Comments are closed.

Up ↑